The 2026 EU-India Free Trade Agreement (FTA) is expected to eliminate tariffs on over 90% of tariff lines. This has altered the cost competitiveness of Indian products and is more of structural reset than merely a trade boost. The tariff elimination drive will improve profit margins by 5-10% for the volume oriented and generic firms, unhoarding funds for reinvestment. Small and medium firms, which contribute to 40% of the exports, can leverage this deal to enter the EU markets, reallocating the savings towards R&D and high standard compliance. In the process, they also gain competitive edge via increased export eligibility, modernized production efficiency, and protection against counterfeit brands in the standardized international market. 

 

As this deal puts India in the EU’s supply chains, it emerges as an alternative to Chinese supply. This positions Indian hubs like Hyderabad and Gujarat on the radar for new facilities by 2028, via production linked incentive synergies. This will also allow technological shift from production of small molecules to high margin segments, thereby improving India’s import resilience. A consequential rise in FDI inflows to the Indian pharma sector could lead to new infrastructure, research facilities and funding, upskilling workforce to keep it all running, resulting into a tangible impact of direct job creation in manufacturing and quality compliance. 

 

The real impact will be powered through joint lab collaborations between Indian and European researchers co-developing chronic disease therapies, expanding treatment options for middle-income and uninsured patients. Post this deal, as India needs to align closely with EU regulatory standards, tighter clinical reporting, transparent labelling and punctilious monitoring of adverse events, quality of drugs both for domestic and international patients will improve. For an average Indian patient, it translates to higher quality medications and fosters long-term public trust in the country’s medical system. 

 

A consequential shift of the deal is stronger intellectual property rights that mirror EU standards. On paper, it makes India an attractive destination for R&D collaboration, but it could mean longer duration of affordable generic medicines to reach patients. Also, lower import costs seem to be good news for the patient but there are severe pricing and affordability gaps in the Indian healthcare system. India’s drug pricing mechanism is highly fragmented and there are serious inconsistencies on the price caping of essential medicines across hospitals. The National Pharmaceutical Pricing Authority has control on only 928 formulations, the others being entirely unregulated. As such there is a real risk that private hospitals and manufacturers will absorb most of the savings and the low-income patients continue to face high healthcare expenses. 

 

From a compliance standpoint, even Gujarat – India's top state for Good Manufacturing Practices (GMP) certification – had only 1,077 GMP-certified drug firms out of thousands operating there, as of May 2024. When the Central Drugs Standard Control Organisation asked the drug manufacturers to submit the upgrade plans by May 2025, only a few firms responded. This makes Indian exporters vulnerable to EU shipment rejections and domestic patients experiencing dubious standards of drugs. 

 

Integrating with EU supply chains will bring efficiency, but it will also make India more dependent on imported advanced therapies and expensive diagnostics, putting more pressure on the already stretched public health budget. But perhaps the most uncomfortable question the deal leaves unanswered is one of equity. Will the gains of the deal serve only the patients in private hospitals with private health insurance, while the rural patients and government hospitals are quietly bypassed? While this is an inevitable outcome, it is a preventable one, only if the policymakers are willing to design explicitly for this cause.